BR112017001725A2 - tratamento de esclerose lateral amiotrófica - Google Patents
tratamento de esclerose lateral amiotróficaInfo
- Publication number
- BR112017001725A2 BR112017001725A2 BR112017001725A BR112017001725A BR112017001725A2 BR 112017001725 A2 BR112017001725 A2 BR 112017001725A2 BR 112017001725 A BR112017001725 A BR 112017001725A BR 112017001725 A BR112017001725 A BR 112017001725A BR 112017001725 A2 BR112017001725 A2 BR 112017001725A2
- Authority
- BR
- Brazil
- Prior art keywords
- lateral sclerosis
- amyotrophic lateral
- sclerosis treatment
- mrna
- treatment
- Prior art date
Links
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 title abstract 3
- 108020004999 messenger RNA Proteins 0.000 abstract 2
- 101100203568 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) sod2 gene Proteins 0.000 abstract 1
- 101100111809 Schizosaccharomyces pombe (strain 972 / ATCC 24843) bsu1 gene Proteins 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 230000007248 cellular mechanism Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 101150062190 sod1 gene Proteins 0.000 abstract 1
- 101150048620 sodN gene Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
- C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
- C12Y115/01001—Superoxide dismutase (1.15.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14341—Use of virus, viral particle or viral elements as a vector
- C12N2750/14343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14306228 | 2014-07-31 | ||
PCT/EP2015/067722 WO2016016449A1 (en) | 2014-07-31 | 2015-07-31 | Treatment of amyotrophic lateral sclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017001725A2 true BR112017001725A2 (pt) | 2018-02-14 |
Family
ID=51298679
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017001725A BR112017001725A2 (pt) | 2014-07-31 | 2015-07-31 | tratamento de esclerose lateral amiotrófica |
Country Status (7)
Country | Link |
---|---|
US (1) | US10590420B2 (pt) |
EP (1) | EP3174981B1 (pt) |
JP (1) | JP6872479B2 (pt) |
BR (1) | BR112017001725A2 (pt) |
CA (1) | CA2955285C (pt) |
ES (1) | ES2806087T3 (pt) |
WO (1) | WO2016016449A1 (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6756700B2 (ja) | 2014-03-18 | 2020-09-16 | ユニバーシティ オブ マサチューセッツ | 筋萎縮性側索硬化症を処置するためのrAAVベースの組成物および方法 |
EP4137573A3 (en) | 2014-04-01 | 2023-05-03 | Biogen MA Inc. | Compositions for modulating sod-1 expression |
KR102599909B1 (ko) | 2014-11-14 | 2023-11-09 | 보이저 테라퓨틱스, 인크. | 근위축성 측삭 경화증(als)을 치료하는 조성물 및 방법 |
RU2749882C2 (ru) | 2014-11-14 | 2021-06-18 | Вояджер Терапьютикс, Инк. | Модулирующие полинуклеотиды |
WO2017136435A1 (en) | 2016-02-01 | 2017-08-10 | The Usa, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer National Institute Of Health | Compounds for modulating fc-epsilon-ri-beta expression and uses thereof |
IL302748A (en) | 2016-05-18 | 2023-07-01 | Voyager Therapeutics Inc | modulatory polynucleotides |
WO2018204786A1 (en) | 2017-05-05 | 2018-11-08 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
AU2018264996A1 (en) | 2017-05-09 | 2019-12-05 | University Of Massachusetts | Methods of treating Amyotrophic Lateral Sclerosis (ALS) |
WO2019028246A2 (en) * | 2017-08-03 | 2019-02-07 | University Of Iowa Research Foundation | METHODS OF TREATING GENETIC HEARING LOSS |
CN111448321A (zh) * | 2017-09-22 | 2020-07-24 | 马萨诸塞大学 | Sod1双表达载体及其用途 |
EP3697908A1 (en) * | 2017-10-16 | 2020-08-26 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
TWI804518B (zh) | 2017-10-16 | 2023-06-11 | 美商航海家醫療公司 | 肌萎縮性脊髓側索硬化症(als)之治療 |
AU2020248392A1 (en) * | 2019-03-26 | 2021-11-11 | Rutgers, The State University Of New Jersey | Compositions and methods for treating neurodegenerative disorders |
JP2022530945A (ja) * | 2019-05-01 | 2022-07-05 | ブラック スワン ファーマシューティカルズ, インコーポレイテッド | Sod1関連疾患に対する処置 |
WO2021089736A1 (en) | 2019-11-06 | 2021-05-14 | Association Institut De Myologie | Combined therapy for muscular diseases |
EP4291654A2 (en) | 2021-02-12 | 2023-12-20 | Alnylam Pharmaceuticals, Inc. | Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases |
WO2023201300A2 (en) * | 2022-04-14 | 2023-10-19 | Shift Pharmaceuticals Holding Inc. | Polynucleotide treatments for charcot-marie-tooth disease |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003000707A2 (en) * | 2001-06-21 | 2003-01-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of superoxide dismutase 1, soluble expression |
FR2874384B1 (fr) | 2004-08-17 | 2010-07-30 | Genethon | Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables |
EP2058401A1 (en) | 2007-10-05 | 2009-05-13 | Genethon | Widespread gene delivery to motor neurons using peripheral injection of AAV vectors |
GB0816778D0 (en) | 2008-09-12 | 2008-10-22 | Isis Innovation | Gene silencing |
US9080170B2 (en) | 2010-03-17 | 2015-07-14 | Association Institut De Myologie | Modified U7 snRNAs for treatment of neuromuscular diseases |
EP2581448B1 (en) | 2011-10-13 | 2015-01-28 | Association Institut de Myologie | Tricyclo-phosphorothioate DNA |
WO2013184209A1 (en) * | 2012-06-04 | 2013-12-12 | Ludwig Institute For Cancer Research Ltd. | Mif for use in methods of treating subjects with a neurodegenerative disorder |
CA2877428A1 (en) | 2012-06-21 | 2013-12-27 | Association Institut De Myologie | Widespread gene delivery of gene therapy vectors |
WO2014172698A1 (en) | 2013-04-19 | 2014-10-23 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation nucleic acids through nonsense mediated decay |
EP4137573A3 (en) * | 2014-04-01 | 2023-05-03 | Biogen MA Inc. | Compositions for modulating sod-1 expression |
-
2015
- 2015-07-31 WO PCT/EP2015/067722 patent/WO2016016449A1/en active Application Filing
- 2015-07-31 BR BR112017001725A patent/BR112017001725A2/pt not_active Application Discontinuation
- 2015-07-31 ES ES15750315T patent/ES2806087T3/es active Active
- 2015-07-31 JP JP2017504740A patent/JP6872479B2/ja active Active
- 2015-07-31 US US15/327,011 patent/US10590420B2/en active Active
- 2015-07-31 EP EP15750315.2A patent/EP3174981B1/en active Active
- 2015-07-31 CA CA2955285A patent/CA2955285C/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2955285A1 (en) | 2016-02-04 |
WO2016016449A1 (en) | 2016-02-04 |
EP3174981A1 (en) | 2017-06-07 |
ES2806087T3 (es) | 2021-02-16 |
EP3174981B1 (en) | 2020-03-25 |
JP2017527276A (ja) | 2017-09-21 |
JP6872479B2 (ja) | 2021-05-19 |
US10590420B2 (en) | 2020-03-17 |
US20170152517A1 (en) | 2017-06-01 |
CA2955285C (en) | 2023-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017001725A2 (pt) | tratamento de esclerose lateral amiotrófica | |
DK3582853T3 (da) | Cykliske dinukleotidforbindelser til behandling af cancer | |
HK1251738A1 (zh) | 用於蜂窩iot的窄帶lte的系統操作的系統和方法 | |
IT201700101704A1 (it) | Nuovo uso per trattamento delle infezioni da clostridium difficile | |
DK3580211T3 (da) | 2-heteroaryl-3-oxo-2,3-dihydropyridazin-4-carboxamider til behandling af cancer | |
MX2018006578A (es) | Formulaciones farmaceuticas topicas para tratar afecciones inflamatorias. | |
EA201890493A1 (ru) | РЕПРЕССОРЫ Htt И ИХ ПРИМЕНЕНИЕ | |
DK3374359T3 (da) | Dihydroimidazopyrazinonderivater, der er nyttige ved behandling af cancer | |
BR112017018179A2 (pt) | acesso múltiplo baseado em contenção de enlace de subida para iot celular. | |
HUE058737T2 (hu) | Eljárások arenaviridae vírusok okozta fertõzések kezelésére | |
BR112017007636A2 (pt) | métodos para a preparação de ribosídeos | |
DK3540122T3 (da) | Poly alpha-1,3-glucanfibrider og anvendelser deraf og fremgangsmåder til fremstilling af poly alpha-1,3-glucanfibrider | |
DK2976360T3 (da) | Terapi, hvori der er involveret antistoffer mod claudin 18.2, til behandling af cancer | |
DK3395354T3 (da) | Plasminogen til anvendelse i behandling af diabetisk nefropati | |
DK3709556T3 (da) | Downlink-kanal-design til lte med lav latens | |
BR112017025711A2 (pt) | ?composições, processo para preparação de siloxanos modificados por poliéter e uso das composições inovadoras? | |
BR112018003526A2 (pt) | métodos de tratamento de doenças inflamatórias | |
DK3391902T3 (da) | Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati | |
BR112015032526A2 (pt) | composições anticaspa e métodos de uso das mesmas | |
ITUA20163081A1 (it) | Tutore gamba-piede alto di scarico. | |
CL2016000351A1 (es) | Método para la cuantificación de actinio-227 en composiciones de radio-223. | |
BR112017022281A2 (pt) | métodos para tratar câncer | |
DK3358001T3 (da) | Clostridium beijerinckii, anvendelse deraf og fremgangsmåde til fremstilling af butanol | |
EP3310266A4 (en) | Rhinoplasty control molds (transverse, axial, basal, final, final splint) | |
DK3662925T3 (da) | Sammensætning, der omfatter fsh, til behandling af infertilitet |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) ; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) ; SORBONNE UNIVERSITE (FR) ; ASSOCIATION INSTITUT DE MYOLOGIE (FR) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) ; SORBONNE UNIVERSITE (FR) ; ASSOCIATION INSTITUT DE MYOLOGIE (FR) |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] |